AXGN
AxoGen, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.7% · net new positions -6.7% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +13 | 31.59M | $1.46B | +13 | −1 |
| Q1 2026 | 88 | +4 | 26.93M | $890.85M | +13 | −9 |
| Q4 2025 | 84 | +1 | 23.54M | $770.31M | +1 | — |
| Q3 2025 | 15 | 0 | 12.88M | $229.79M | +1 | −2 |
| Q2 2025 | 13 | -3 | 10.16M | $110.24M | — | −3 |
| Q1 2025 | 13 | +1 | 4.00M | $74.03M | +1 | — |
| Q4 2024 | 12 | +1 | 2.94M | $48.52M | +2 | −1 |
| Q3 2024 | 10 | +4 | 2.95M | $41.31M | +4 | — |
| Q2 2024 | 6 | — | 2.53M | $18.31M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.61M | +3.1% | $64.39M | 0.0% | ▲ Add | 2 | SEC ↗ ×11 |
| 2 | The Vanguard Group ✦ (passive) | 2.68M | -1.9% | $47.80M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Morgan Stanley ✦ | 2.43M | — | $43.35M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 4 | State Street Global Advisors ✦ (passive) | 1.11M | -1.1% | $19.81M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.08M | +1.8% | $19.26M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 488.83K | +1578.6% | $8.72M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | JPMorgan Chase ✦ | 418.01K | — | $7.46M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | Goldman Sachs Group ✦ | 286.59K | — | $5.11M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 187.31K | -70.8% | $3.34M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 174.14K | -61.2% | $3.11M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 156.33K | +1326.4% | $2.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Fidelity (FMR) ✦ | 134.89K | -49.8% | $2.41M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 13 | Citadel Advisors ✦ | 44.31K | New | $790,455 | 0.0% | New | 1 | SEC ↗ |
| 14 | Millennium Management ✦ | 41.23K | -60.5% | $735,579 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 40.66K | +3.2% | $726,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $790,455 | 0.0% |
Exited
| Renaissance Technologies | $1.54M | was 0.0% |
| Norges Bank | $662,935 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 219 holders, 49.68M shares, $1.61B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.50K sh · $173,940
Director · 13.35K sh · $646,592
Officer · 67.50K sh · $3.20M
Director · 14.15K sh · $640,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology